The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide Federal Register :: Revocation of Emergency Use of a Drug During the COVID 19 Pandemic; Availability FDA takes first step in possible reversal of ban on some peptides The Washington Post BPC 157 Arginate Therapy for your Healing Simply Wellness Recovery Peptide Blend (BPC 157 TB 500 KPV) in Houston Huemn Healing Peptide Therapy